

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

TNF

RRID:AB_396761

Type: Antibody

Proper Citation

BD Biosciences Cat# 557644, RRID:AB_396761

Antibody Information

URL: http://antibodyregistry.org/AB_396761

Proper Citation: BD Biosciences Cat# 557644, RRID:AB_396761

Target Antigen: TNF

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Intracellular staining (flow cytometry)

Antibody Name: TNF

Description: This monoclonal targets TNF

Target Organism: mouse

Antibody ID: AB_396761

Vendor: BD Biosciences

Catalog Number: 557644

Record Creation Time: 20250819T225803+0000

Record Last Update: 20250820T035220+0000

Ratings and Alerts

No rating or validation information has been found for TNF.

No alerts have been found for TNF.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. *Cancer cell*, 44(5), 1080.

Chen J, et al. (2025) Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors. *Cell reports. Medicine*, 6(9), 102306.

Yang Z, et al. (2025) A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza a viruses. *Vaccine*, 65, 127776.

Zhang J, et al. (2025) Thymic dendritic cell-derived IL-27p28 promotes the establishment of functional bias against IFN- γ production in newly generated CD4 $^{+}$ T cells through STAT1-related epigenetic mechanisms. *eLife*, 13.

Lin H, et al. (2024) Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. *Cancer cell*, 42(12), 2032.

Pitter MR, et al. (2024) PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages. *Cell reports*, 43(3), 113942.

Hao J, et al. (2024) NR4A1 transcriptionally regulates the differentiation of stem-like CD8 $^{+}$ T cells in the tumor microenvironment. *Cell reports*, 43(6), 114301.

Yu J, et al. (2024) Progesterone-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell*, 187(17), 4713.

Liao P, et al. (2022) CD8 $^{+}$ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. *Cancer cell*, 40(4), 365.

Mudalagiriappa S, et al. (2022) GM-CSF $^{+}$ Tc17 cells are required to bolster vaccine immunity against lethal fungal pneumonia without causing overt pathology. *Cell reports*, 41(4), 111543.

Enriquez AB, et al. (2022) Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict Th17 polarization during infection. *iScience*, 25(5), 104305.

Cannons JL, et al. (2021) PI3K γ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8 $^{+}$ T cells at the expense of central memory. *Cell reports*, 37(2), 109804.

Lin H, et al. (2021) Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. *Cancer cell*, 39(4), 480.

Budhu S, et al. (2021) Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. *Cell reports*, 34(2), 108620.

Zhang W, et al. (2021) The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. *Immunity*, 54(6), 1168.

Gomez-Lopez N, et al. (2020) Regulatory T Cells Play a Role in a Subset of Idiopathic Preterm Labor/Birth and Adverse Neonatal Outcomes. *Cell reports*, 32(1), 107874.

Gurusamy D, et al. (2020) Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. *Cancer cell*, 37(6), 818.

Li W, et al. (2018) Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. *Cell metabolism*, 28(1), 87.

Li J, et al. (2018) Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8⁺ T Cells. *Immunity*, 48(4), 773.